Methionine-restricted diet and gut microbiota
Official title: Shaping Gut Microbiota Through a Dietary Intervention to Regulate Inflammatory Processes
Run by Centre hospitalier de l'Université de Montréal (CHUM) · NCT07283328 · Data updated 2026-11-12
We will test whether a methionine-restricted diet changes gut bacteria and inflammation in healthy adults aged 20–50.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 20 Years to 50 Years |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Centre hospitalier de l'Université de Montréal (CHUM) Academic / other |
| Locations | 1 site (Montreal, Quebec) |
| Status | Recruiting |
| Started | August 20, 2024 |
| Main results expected | March 2026 |
| Study ends | March 2026 |
| Registry record updated | December 22, 2025 |
| Trial ID | NCT07283328 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Healthy omnivorous adults aged 20–50 who can follow a controlled diet, attend in-person visits, and understand French or English are ideal candidates.
✕Probably not a fit
People with active inflammatory or infectious disease, B12 deficiency, significant liver or kidney dysfunction, insulin-dependent diabetes, active cancer, pregnancy or lactation, eating disorders, severe food allergies, or other conditions preventing adherence are excluded and unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a randomized, crossover pilot with 40 healthy omnivorous adults who complete baseline, methionine-restricted (MR) diet, and supplementation/placebo periods over 10 weeks. Participants are randomized to receive either MR plus 1,500 mg daily methionine or MR plus placebo for two-week blocks, then cross over to the alternate supplement arm. Gut microbiota composition, blood methionine and metabolite levels, and immune/inflammatory markers are measured every two weeks. The design tests whether short-term dietary methionine restriction and controlled resupply alter microbiota and systemic inflammatory signals in humans.
Why it matters
Potential benefit: If successful, this approach could offer a simple dietary strategy to shift gut microbes and lower inflammation that might inform prevention or modification of immune-driven diseases.
How similar studies have gone: Animal studies and observational human data suggest methionine restriction can alter immunity and the microbiota, but randomized crossover intervention data in humans are limited and this design is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Healthy adults * 20-50 years old * On omnivorous/western diet * Understanding French or English Exclusion Criteria: * B12 deficiency * Glomerular filtration rate \<75 ml/h * Liver dysfunction * Pregnant or lactating * Active inflammatory or infectious disease * Insulino-dependent diabetes * Active cancer * Eating disorder * BMI \< 18.5 kg/m2 * Severe food allergies or intestinal problems or active substance dependence that would prevent adherence to the experimental diet
Where it's running
-
Centre de recherche du Centre Hospitalier de l'Université de Montréal
Montreal, Quebec, Canada Recruiting
Study contacts
- Study coordinator: Catherine Larochelle, MD, PhD
- Email: catherine.larochelle.med@ssss.gouv.qc.ca
- Phone: 514 890-8000
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Laser-based sizing of GI lesions during endoscopies
This study tests whether the AccuMeasure laser tool gives more accurate and reliable lesion size measurements during colonoscopies for adults with colon polyps or Crohn’s disease than traditional endoscopic estimates.
-
Restrictive fluid strategy with phlebotomy during liver transplantation
This study tests whether a restrictive fluid plan with phlebotomy during liver transplant helps patients recover better than a more fluid-intensive plan.
-
Mobile app to help adults in Quebec use cannabis more safely
A mobile app is being tested to see if it helps adults who use cannabis non-medically in Quebec use cannabis more safely.
-
Adaptive external beam radiotherapy added to Lutetium-177 PSMA therapy for metastatic castration-resistant prostate cancer
This trial tests whether adding targeted external beam radiotherapy during Lutetium-177 PSMA treatment can improve outcomes for men with metastatic castration‑resistant prostate cancer.
-
KAN-004 treatment for immune-related diarrhea and colitis
This trial is testing whether KAN-004 is safe and tolerable for adults who develop moderate-to-severe diarrhea or colitis after treatment with immune checkpoint inhibitors.
-
Reducing long-term pain after lung resection using transthoracic, out-of-cage, or hybrid robotic approaches
We will test whether using subcostal/subxiphoid ('out of cage') or a hybrid robotic approach causes less chronic pain than standard transthoracic robotic surgery in adults having lung resection.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.